Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.53 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.46 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631720 | 0.92 | ITPR3 (0.47) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL28707 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4538834 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4518749 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4521470 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4529975 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4526591 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4539050 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4532688 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL4527399 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1ITPR3ITPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045750-B2 | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 | MA YUELONG (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | MA YUELOG (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | AGO2, HNRNPH3, HCLS1 | LPAR3 1809/4885LPAR2 3291/4885LPAR1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.